Dosing and Administration

Oncaspar® is given in a dose of 2,500 IU/m2 intramuscularly (IM) or intravenously (IV) no more frequently than every 14 days1.

Oncaspar® offers sustained asparagine depletion with less frequent dosing and administration

Pegylation increases the half-life of asparaginase...2

Half-life of 3 Asparaginase Preparations2
Formulation
Elimination Half-life
Erwinia Asparaginase
16 hours
Native E. coli L-asparaginase
26-30 hours
Pegylated L-asparaginase
5.5-7 days

…resulting in fewer doses1

Administration of Oncaspar
IM Administration: Limit the volume at a single injection site to 2 mL; if greater than 2 mL, use multiple injection sites.1
IV Administration: Give over a period of 1 to 2 hours in 100 mL of sodium chloride or dextrose injection 5% through an infusion that is already running.1
Note

Do not administer Oncaspar if drug1:

  • Has been frozen
  • Has been stored at room temperature for more than 48 hours
  • Has been shaken or vigorously agitated
  • Is cloudy , discolored, and/or precipitate is present

One dose of Oncaspar® 2500 IU/m2 achieved similar levels of asparagine depletion as 9 doses of native E. coli L-asparaginase during induction and 6 doses during each delayed intensification phase.1

Oncaspar can be administered through IM or IV injection1
1 IV infusion of Oncaspar = 9 IM injections* of native E. coli L-asparaginase during induction


IM = intramuscular, IV = intravenous.
*One to 6 conversion of Oncaspar to native E. coli L-asparaginase in other phases of treatment.


References:

1. Oncaspar® [prescribing information].
2. Avramis VI, Panosyan EH. Pharmacokinetic/Pharmacodynamic relationships of asparaginase formulations. Clin Pharmacokinet. 2005;44:367-393.

Back to top

S.O.S.

Sigma-Tau Outreach Services
For more details on this resource, click here.

Call 1-800-490-3262

Indication

ONCASPAR® (pegaspargase) is indicated as a component of a multiagent chemotherapeutic regimen for the first–line treatment of patients with acute lymphoblastic leukemia (ALL) and for the treatment of patients with ALL and hypersensitivity to native forms of L-asparaginase.

Important Safety Information

Oncaspar® is contraindicated in patients with a history of serious allergic reactions to Oncaspar, and in patients with a history of serious thrombosis, pancreatitis, or serious hemorrhagic events with prior L-asparaginase therapy.

Anaphylaxis or serious allergic reactions can occur; therefore, patients should be observed for one hour after administration. Discontinue Oncaspar in patients with serious allergic reactions. Patients with abdominal pain should be evaluated for evidence of pancreatitis. Discontinue Oncaspar in patients with pancreatitis. Oncaspar should also be discontinued in patients with serious thrombotic events.

Glucose intolerance, in some cases irreversible, can occur; serum glucose should be monitored. Coagulopathy and hepatotoxicity can occur; appropriate monitoring should be performed.

The most common adverse reactions with Oncaspar® (≥2%) are allergic reactions (including anaphylaxis), hyperglycemia, pancreatitis, central nervous system (CNS) thrombosis, coagulopathy, hyperbilirubinemia, and elevated transaminases.

Hyperlipidemia (hypercholesterolemia and hypertriglyceridemia) has been reported in patients exposed to Oncaspar. Please click here to review full Product Information.